Evidence map›Paper›PMID 25295077›Full record

ArticleOncology letters2014

Overexpression of the Survivin gene in SGC7901 cell resistance to cisplatin.

Hanzhang Dong, Gaogao Liu, Biao Jiang, Jiubing Guo, Guoquan Tao, Wei Yiu, Jingsong Zhou, Guoxin Li

Abstract read
In one paragraph

Article in Oncology letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hanzhang DongDepartment of General Surgery, The Affiliated Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
Gaogao LiuDepartment of General Surgery, The Affiliated Beijiao Hospital of Southern Medical University, Shunde, Guangdong 528311, P.R. China.
Biao JiangDepartment of General Surgery, The Affiliated Beijiao Hospital of Southern Medical University, Shunde, Guangdong 528311, P.R. China.
Jiubing GuoDepartment of General Surgery, The Affiliated Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
Guoquan TaoDepartment of General Surgery, The Affiliated Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
Wei YiuDepartment of General Surgery, The Affiliated Beijiao Hospital of Southern Medical University, Shunde, Guangdong 528311, P.R. China.
Jingsong ZhouDepartment of General Surgery, The Affiliated Beijiao Hospital of Southern Medical University, Shunde, Guangdong 528311, P.R. China.
Guoxin LiDepartment of General Surgery, The Affiliated Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the present study was to investigate the mechanism of SGC7901 cell resistance to cisplatin (CDDP). SGC7901/CDDP cells were established by the long-term continuous exposure of SGC7901 cells to CDDP in stepwise concentration increments. The morphologies of the SGC7901/CDDP and SGC7901 cells were observed by microscopy. The expression levels of Survivin mRNA and protein in the SGC7901/CDDP and SGC7901 cells were examined by reverse transcription polymerase chain reaction and western blotting respectively. The results revealed morphological differences between the SGC7901 and SGC7901/CDDP cells. The expression levels of Survivin mRNA and protein were significantly higher in the SGC7901/CDDP cells than in the SGC7901 cells. Therefore, high expression levels of the Survivin gene may explain SGC7901 cell resistance to CDDP.

Indexed as

chemotherapycisplatingastric cancerSurvivin

Identifiers

PMID25295077
PMCPMC4186609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.